Dr. Wang on the Safety Profile of KTE-X19 in MCL
In Partnership With:
Michael Wang, MD, discusses the safety profile of the CAR T-cell therapy KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, according to results from the phase II ZUMA-2 trial.
Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the safety profile of the CAR T-cell therapy KTE-X19 in patients with relapsed/refractory mantle cell lymphoma (MCL), according to results from the phase II ZUMA-2 trial.
At a median follow-up of 12.3 months, results from the ZUMA-2 trial showed an overall response rate of 93% with a complete response rate of 67%. These results led to the FDA granting KTE-X19 priority review in patients with relapsed/refractory MCL.
KTE-X19 also had a tolerable safety profile, according to Wang. Out of 68 patients, 15% experienced grade 3 cytokine release syndrome (CRS) and 30% experienced neurotoxicity. No patients died from CRS or neurotoxicity and the majority of CRS and neurotoxicity is reversible. Meanwhile, 2 patients died from infections due to the CAR T-cell therapy, concludes Wang.
